These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

682 related articles for article (PubMed ID: 16356796)

  • 1. Nuclear medicine studies of the prostate, testes, and bladder.
    Jana S; Blaufox MD
    Semin Nucl Med; 2006 Jan; 36(1):51-72. PubMed ID: 16356796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography for prostate, bladder, and renal cancer.
    Schöder H; Larson SM
    Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron emission tomography and bone metastases.
    Fogelman I; Cook G; Israel O; Van der Wall H
    Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer.
    De Visschere PJL; Standaert C; Fütterer JJ; Villeirs GM; Panebianco V; Walz J; Maurer T; Hadaschik BA; Lecouvet FE; Giannarini G; Fanti S
    Eur Urol Oncol; 2019 Feb; 2(1):47-76. PubMed ID: 30929846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent developments in urologic oncology: positron emission tomography molecular imaging.
    Bouchelouche K; Oehr P
    Curr Opin Oncol; 2008 May; 20(3):321-6. PubMed ID: 18391633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 11C-choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer.
    Rinnab L; Blumstein NM; Mottaghy FM; Hautmann RE; Küfer R; Hohl K; Reske SN
    BJU Int; 2007 Jun; 99(6):1421-6. PubMed ID: 17355373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.
    Oyama N; Miller TR; Dehdashti F; Siegel BA; Fischer KC; Michalski JM; Kibel AS; Andriole GL; Picus J; Welch MJ
    J Nucl Med; 2003 Apr; 44(4):549-55. PubMed ID: 12679398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choline-PET in prostate cancer management: the point of view of the radiation oncologist.
    De Bari B; Alongi F; Lestrade L; Giammarile F
    Crit Rev Oncol Hematol; 2014 Sep; 91(3):234-47. PubMed ID: 24813466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET in the management of urologic malignancies.
    Kumar R; Zhuang H; Alavi A
    Radiol Clin North Am; 2004 Nov; 42(6):1141-53, ix. PubMed ID: 15488563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Positron emission tomography (PET) for diagnosis and monitoring of treatment for urological tumors].
    Machtens S; Boerner AR; Hofmann M; Knapp WH; Jonas U
    Urologe A; 2004 Nov; 43(11):1397-409. PubMed ID: 15502907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positron emission tomography for radiation treatment planning.
    Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
    Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast.
    Langsteger W; Heinisch M; Fogelman I
    Semin Nucl Med; 2006 Jan; 36(1):73-92. PubMed ID: 16356797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
    Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
    Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complimentary role of FDG-PET imaging and skeletal scintigraphy in the evaluation of patients of prostate carcinoma.
    Tiwari BP; Jangra S; Nair N; Tongaonkar HB; Basu S
    Indian J Cancer; 2010; 47(4):385-90. PubMed ID: 21131750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Visualization of prostate cancer with 11C-choline positron emission tomography (PET): localization of primary and recurrent prostate cancer].
    Kanda T; Nakagomi K; Goto S; Torizuka T
    Hinyokika Kiyo; 2008 May; 54(5):325-32. PubMed ID: 18546855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET in prostate and bladder tumors.
    Lee ST; Lawrentschuk N; Scott AM
    Semin Nucl Med; 2012 Jul; 42(4):231-46. PubMed ID: 22681672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
    Cirillo S; Petracchini M; D'Urso L; Dellamonica P; Illing R; Regge D; Muto G
    BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET/CT and radiotherapy in prostate cancer.
    De Jong IJ; De Haan TD; Wiegman EM; Van Den Bergh AC; Pruim J; Breeuwsma AJ
    Q J Nucl Med Mol Imaging; 2010 Oct; 54(5):543-52. PubMed ID: 20927021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer: role of SPECT and PET in imaging bone metastases.
    Beheshti M; Langsteger W; Fogelman I
    Semin Nucl Med; 2009 Nov; 39(6):396-407. PubMed ID: 19801219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.